{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:03:29Z","timestamp":1792440209575,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018679","name":"HLS Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.medj.2022.12.008","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T13:44:42Z","timestamp":1673358282000},"page":"130-138.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease"],"prefix":"10.1016","volume":"4","author":[{"given":"Aishwarya","family":"Krishnaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Bakbak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Puar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaavani","family":"Lambotharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aathmika","family":"Kirubaharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene N.","family":"Firoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gus","family":"Meglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaratnam","family":"Kirubaharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Vijayaraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Demchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Voisine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2022.12.008_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000580","article-title":"Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American heart association","volume":"138","author":"Volgman","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.medj.2022.12.008_bib2","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2022.12.008_bib3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2337\/dc13-2656","article-title":"Understanding the high prevalence of diabetes in U.S. south Asians compared with four racial\/ethnic groups: the MASALA and MESA studies","volume":"37","author":"Kanaya","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medj.2022.12.008_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2022.12.008_bib5","series-title":"Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting Presentation (November 14, 2019)","author":"Sharretts","year":"2019"},{"key":"10.1016\/j.medj.2022.12.008_bib6","first-page":"1570","article-title":"The morphology of coronary artery disease in South Asians vs white caucasians and its implications","volume":"38","author":"Hosseini","year":"2022","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.medj.2022.12.008_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/HCO.0000000000000800","article-title":"Generalizability of Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial in patients with a history of coronary artery bypass graft surgery","volume":"36","author":"Kosmopoulos","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.medj.2022.12.008_bib8","doi-asserted-by":"crossref","first-page":"e022937","DOI":"10.1161\/JAHA.121.022937","article-title":"Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI","volume":"11","author":"Peterson","year":"2022","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.medj.2022.12.008_bib9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: reduce-it CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.medj.2022.12.008_bib10","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.medj.2022.12.008_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2022.12.008_bib12","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S2468-2667(22)00006-8","article-title":"Relative contribution of trends in myocardial infarction event rates and case fatality to declines in mortality: an international comparative study of 1.95 million events in 80.4 million people in four countries","volume":"7","author":"Camacho","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.medj.2022.12.008_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12170-019-0618-9","article-title":"Lipids in South Asians: epidemiology and management","volume":"13","author":"Makshood","year":"2019","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"10.1016\/j.medj.2022.12.008_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/01.STR.32.5.1069","article-title":"Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease","volume":"32","author":"Kain","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.medj.2022.12.008_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cyto.2012.09.002","article-title":"Circulating IL-6 concentrations and associated anthropometric and metabolic parameters in South Asian men and women in comparison to European whites","volume":"61","author":"Peters","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.medj.2022.12.008_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0021-9150(00)00684-5","article-title":"Impaired fibrinolysis and increased fibrinogen levels in South Asian subjects","volume":"156","author":"Kain","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medj.2022.12.008_bib17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.ATV.0000135845.95890.4e","article-title":"C-reactive protein as a screening test for cardiovascular risk in a multiethnic population","volume":"24","author":"Anand","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.medj.2022.12.008_bib18","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.medj.2022.12.008_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(00)02502-2","article-title":"Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)","volume":"356","author":"Anand","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2022.12.008_bib20","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.medj.2022.12.008_bib21","doi-asserted-by":"crossref","first-page":"108204","DOI":"10.1016\/j.jdiacomp.2022.108204","article-title":"Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes","volume":"36","author":"Limonte","year":"2022","journal-title":"J.\u00a0Diabetes Complications"},{"key":"10.1016\/j.medj.2022.12.008_bib22","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.medj.2022.12.008_bib23","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634022005244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634022005244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:56:43Z","timestamp":1763002603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634022005244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666634022005244"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2022.12.008","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2022.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}